Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 7:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Citalopram Clear all
Completed Phase 3 Interventional Results available

Escitalopram in Adult Patients With Major Depressive Disorder

NCT00668525
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
45
States / cities
Phoenix, Arizona • Arcadia, California • Encino, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 4 Interventional Results available

A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder

NCT03924323
View directory record Official record
Conditions
Anxiety Disorders,Generalized Anxiety Disorder
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
7 Years to 17 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
39
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation

NCT00794040
View directory record Official record
Conditions
Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Add-on citalopram following optimized methylphenidate, Add-on placebo following optimized methylphenidate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Aripiprazole and Lexapro Drug Interaction Study

NCT00361790
View directory record Official record
Conditions
Healthy
Interventions
Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 4 Interventional

Treatment of Depression in Adults

NCT00073697
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Interpersonal Psychotherapy, Escitalopram plus IPT
Drug · Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 66 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 4 Interventional

Escitalopram for the Treatment of Self-Injurious Skin Picking

NCT00115011
View directory record Official record
Conditions
Impulse Control Disorders
Interventions
Escitalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

Citalopram in Irritable Bowel Syndrome

NCT00477165
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Citalopram, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 27, 2026, 7:42 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111565
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Tucson, Arizona • Chino, California • Riverside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 4 Interventional

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

NCT00595699
View directory record Official record
Conditions
Major Depression, Temporal Lobe Epilepsy
Interventions
escitalopram, placebo
Drug
Lead sponsor
Conrad, Erich J., M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2011 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study of Escitalopram in the Treatment of Specific Phobia

NCT00121069
View directory record Official record
Conditions
Phobic Disorders
Interventions
Escitalopram
Drug
Lead sponsor
Connor, Kathryn M., M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2005 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 2 Interventional

Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)

NCT00249405
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse
Interventions
Citalopram + MI, Placebo + MI
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
21 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Sep 27, 2026, 7:42 AM EDT
Completed No phase listed Observational

EEG Biomarkers for Predicting Response to Antidepressant Therapy

NCT00289523
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Medtronic - MITG
Industry
Eligibility
21 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 4 Interventional

Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro)

NCT00296790
View directory record Official record
Conditions
Insomnia
Interventions
zolpidem tartrate
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 64 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 11, 2007 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 2 Interventional

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

NCT00086645
View directory record Official record
Conditions
Autistic Disorder
Interventions
citalopram hydrobromide, placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
5 Years to 17 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Lebanon, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 4 Interventional Results available

Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression

NCT00177294
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Interpersonal Psychotherapy, Clinical Monitoring
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

Citalopram to Enhance Cognition in HD

NCT00271596
View directory record Official record
Conditions
Huntington Disease, Chorea, Executive Dysfunction
Interventions
20mg daily citalopram, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Effects of Escitalopram and Citalopram Using fMRI

NCT00825825
View directory record Official record
Conditions
Antidepressant Activity in Healthy Volunteers
Interventions
Escitalopram, Citalopram, Placebo
Drug
Lead sponsor
Michael Henry, MD
Other
Eligibility
21 Years to 50 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Sep 27, 2026, 7:42 AM EDT
Suspended Phase 2 Interventional

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

NCT06705478
View directory record Official record
Conditions
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
Interventions
Pramipexole ER, Escitalopram
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

NCT01045083
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO4917523, escitalopram, methylphenidate, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 27, 2026, 7:42 AM EDT
Active, not recruiting Phase 3 Interventional

Escitalopram for Agitation in Alzheimer's Disease

NCT03108846
View directory record Official record
Conditions
Dementia
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years to 109 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
22
States / cities
Sun City, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Escitalopram Oxalate Tablets 20 mg to Lexapro® Tablets 20 mg

NCT00648661
View directory record Official record
Conditions
Healthy
Interventions
Escitalopram Oxalate Tablets 20 mg, Lexapro® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 4 Interventional Results available

Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)

NCT03128021
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram Pill, Placebo, Levomilnacipran Pill
Drug · Other
Lead sponsor
Howard Aizenstein
Other
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 27, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

SSRI and Buprenorphine

NCT00475878
View directory record Official record
Conditions
Opiate Dependence, Depression
Interventions
escitalopram, placebo
Drug
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Sep 27, 2026, 7:42 AM EDT
Enrolling by invitation Phase 2 Interventional

Neuroimaging of Escitalopram in Autism Spectrum Disorder

NCT06826326
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Escitalopram 10mg, Placebo
Drug
Lead sponsor
Kathryn Unruh
Other
Eligibility
12 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 27, 2026, 7:42 AM EDT